Database Query Results : Arsenic trioxide, ,

ATO, Arsenic trioxide: Click to Expand ⟱
Features:
Arsenic has been known for centuries for its toxic and medicinal properties. Although once infamously used as a poison, ongoing research has repurposed arsenic derivatives for medicinal use.

Arsenic trioxide — Arsenic trioxide (As2O3) is an intravenously administered inorganic small-molecule antileukemic agent best known for targeting acute promyelocytic leukemia (APL) biology, where it promotes degradation of the PML–RARα oncoprotein and restores differentiation programs while also engaging oxidative/mitochondrial stress pathways. It is a regulated prescription drug (injectable solution; oncology use). Standard abbreviation(s): ATO. Clinically, it is established therapy for APL (including in combination with all-trans retinoic acid, ATRA/tretinoin) and requires strict cardiac/electrolyte and toxicity monitoring due to potentially fatal QT prolongation/arrhythmia and other boxed-warning risks.

Primary mechanisms (ranked):

  1. PML–RARα oncoprotein damage/degradation with downstream re-formation of PML nuclear bodies, differentiation reprogramming, and loss of leukemia-initiating capacity (APL-centric)
  2. Pro-apoptotic stress signaling (mitochondrial dysfunction, DNA fragmentation phenotype in APL models)
  3. Oxidative stress and redox remodeling with downstream stress-response signaling (context-dependent; contributes to cytotoxicity and/or sensitization)
  4. Metabolic suppression in some solid-tumor models (e.g., glycolysis/LDHA axis inhibition reported in specific contexts; not a primary, label-defined mechanism)

Bioavailability / PK relevance: Delivered IV (standard clinical product). In solution it forms arsenious acid (AsIII), the pharmacologically active species; major circulating metabolites include MMAV and DMAV with longer half-lives and greater accumulation vs AsIII. AsIII shows wide tissue distribution (large Vss). Exposure is regimen-driven (oncology dosing) rather than “nutraceutical-like” oral titration; oral ATO exists in research/region-specific formulations but is not the default reference for labeled TRISENOX use.

In-vitro vs systemic exposure relevance: Many mechanistic findings outside APL (ROS/metabolic axes) are concentration- and model-dependent; do not assume that solid-tumor in-vitro concentrations map cleanly onto clinically tolerated systemic exposure given dose-limiting cardiac and systemic toxicities.

Clinical evidence status: Established, guideline-level therapy in APL with randomized phase 3 evidence supporting ATRA+ATO regimens in low/intermediate-risk APL; also indicated for relapsed/refractory APL. Broader “anti-glycolysis/anti-migration” positioning is preclinical/adjunct-hypothesis level outside APL.

Arsenic trioxide — cancer-relevant mechanistic axes (ranked)

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 PML–RARα proteostasis and differentiation program ↓ PML–RARα (APL); ↑ differentiation; ↓ self-renewal capacity Not target-defining in most normal tissues G Oncoprotein elimination and differentiation-based disease control Core, clinically validated axis in APL; most “ATO = drug” value is anchored here.
2 Cardiac electrophysiology constraint — ↑ QTc risk; ↑ torsade risk (with electrolyte/QT-prolonging co-meds) P/R Dose-limiting safety axis Boxed warning includes QT prolongation/ventricular arrhythmias; mandates ECG + K/Mg management.
3 Apoptosis and DNA fragmentation phenotype ↑ apoptosis (APL models); ↑ DNA fragmentation phenotype Context-dependent toxicity R Cytotoxic stress response Mechanism is “not completely understood” on label; apoptosis phenotype is consistently described for APL cell models.
4 Mitochondria and bioenergetics ↓ ATP (model-dependent) Context-dependent mitochondrial toxicity R Bioenergetic stress Nestronics indexing flags ATP↓ in cancer/diseased cells; often mechanistically tied to ROS/apoptosis networks rather than a single ETC target.
5 ROS and redox stress (secondary) ↑ ROS (context-dependent); redox-driven signaling shifts ↑ oxidative stress risk (context-dependent) P/R Stress amplification and sensitization potential Frequently invoked in preclinical literature; translation constrained by systemic toxicity and disease context.
6 Core metabolism / glycolysis axis ↓ glycolysis (model-dependent); ↓ lactate production; ↓ LDHA/PGK1/PGM1 (reported in specific models) ↔ / context-dependent G Metabolic suppression in select tumor models Nestronics pathways emphasize glycolysis-related downshifts (solid-tumor paper indexing). Outside APL, treat as hypothesis-level and model-specific.
7 Migration / invasion phenotype ↓ migration/invasion phenotypes (model-dependent) ↔ G Anti-motility signaling (context-dependent) Nestronics flags reduced tumor cell invasion/migration/proliferation phenotypes; not a label-defined therapeutic claim.
8 Drug resistance and efflux ↑ efflux signatures (model-dependent) ↔ G Adaptive resistance pressure Nestronics flags efflux ↑ as a resistance axis; clinically, regimen design and monitoring dominate over “efflux targeting.”
9 Clinical Translation Constraint APL benefit is high; broad solid-tumor translation limited Systemic toxicity limits exposure — Therapeutic window and monitoring burden Key constraints: QTc prolongation/arrhythmia risk, differentiation syndrome risk, encephalopathy/Wernicke’s risk, hepatic/renal impairment considerations; IV delivery standard for TRISENOX.

TSF legend: P: 0–30 min   R: 30 min–3 hr   G: >3 hr
Scientific Papers found: Click to Expand⟱
5372- ATO,    Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
- Trial, APL, NA
Remission↑, OS↑, toxicity↓,
5373- ATO,    arsenic trioxide
- Human, APL, NA
Half-Life↝,
5374- ATO,    A pharmacokinetic and safety study of oral arsenic trioxide in patients with acute promyelocytic leukemia
- Trial, APL, NA
toxicity↓, OS↑,
5375- ATO,    Improved Outcome with ATRA-Arsenic Trioxide Compared to ATRA-Chemotherapy in Non-High Risk Acute Promyelocytic Leukemia – Updated Results of the Italian-German APL0406 Trial on the Extended Final Series
- Trial, APL, NA
eff↑, OS↑,
3143- VitC,  ATO,    Vitamin C enhances the sensitivity of osteosarcoma to arsenic trioxide via inhibiting aerobic glycolysis
- in-vitro, OS, NA
TumCP↓, TumCMig↓, TumCI↓, eff↑, Glycolysis↓, lactateProd↓, ATP↓, PGK1↓, PGM1↓, LDHA↓,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 5

Pathway results for Effect on Cancer / Diseased Cells:


Mitochondria & Bioenergetics ⓘ

ATP↓, 1,  

Core Metabolism/Glycolysis ⓘ

Glycolysis↓, 1,   lactateProd↓, 1,   LDHA↓, 1,   PGK1↓, 1,   PGM1↓, 1,  

Migration ⓘ

TumCI↓, 1,   TumCMig↓, 1,   TumCP↓, 1,  

Drug Metabolism & Resistance ⓘ

eff↑, 2,   Half-Life↝, 1,  

Functional Outcomes ⓘ

OS↑, 3,   Remission↑, 1,   toxicity↓, 2,  
Total Targets: 14

Pathway results for Effect on Normal Cells:


Total Targets: 0

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:337  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page